HER2 Support Group Forums - The continuing development of oncology

Here the abstract of the highlights of the International Expert Consensus on the Primary Therapy of Early BC 2007, from the current issue of the Annals of Oncology:

special article

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

A Goldhirsch1,*, WC Wood2, RD Gelber3, AS Coates4, B Thürlimann5, H-J Senn6 and Panel Membershttp://annonc.oxfordjournals.org/math/link//dagger.gif

1 International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland and European Institute of Oncology, 20141 Milan, Italy
2 Department of Surgery, Emory University School of Medicine, N. E. Atlanta, GA 30322, USA
3 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
4 International Breast Cancer Study Group and University of Sydney, Sydney, NSW 2006, Australia
5 Division of Gynecologic Oncology, Kantonsspital, 9006 St Gallen, Switzerland
6 Tumor-Center ZeTuP (Detection, Treatment, Prevention), 9006 St Gallen, Switzerland
* Correspondence to: Dr A. Goldhirsch, International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. E-mail: aron.goldhirsch@ibcsg.org<SCRIPT type=text/javascript></SCRIPT>

The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone receptors are targets for endocrine therapies. An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy. Three categories were acknowledged: highly endocrine responsive, incompletely endocrine responsive and endocrine non-responsive. The Panel accepted HER2-positivity to assign trastuzumab, and noted that adjuvant trastuzumab has only been assessed together with chemotherapy. They largely endorsed previous definitions of risk categories. While recognizing the existence of several molecularly-based tools for risk stratification, the Panel preferred to recommend the use of high-quality standard histopathological assessment for both risk allocation and target identification. Chemotherapy, although largely lacking specific target information, is the only option in cases which are both endocrine receptor-negative and HER2-negative. Chemotherapy is conventionally given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice. 
<HR align=left width="50%" noShade SIZE=1>http://annonc.oxfordjournals.org/math/dagger.gif See Appendix for members of the Panel. 
Received for publication April 30, 2007. Accepted for publication May 2, 2007.

link: http://annonc.oxfordjournals.org/cgi...ract/18/7/1133

Hopeful